Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 335

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 335
---
 among other companies, Deutsche Bank, Morgan Stanley, and Merrill Lynch. Mr. Worman is an accomplished and diverse
financial services executive with a history of providing strong, effective leadership and developing and executing strategy across a spectrum
of businesses. With nearly four decades of experience, he is adept at organizational analysis and implementing change, ensuring proper
controls and sources of liquidity are in place, and advising executive management on business direction. Mr. Worman’s prior
experience in senior finance and chief operating officer positions in corporate finance, fixed income and equity capital markets, wealth
management, investment management, strategic analysis, interdealer brokerage, and compliance underscore his ability to handle industry
segment and public company chief financial officer requirements. Mr. Worman earned a BS degree from Ramapo College of New Jersey
and an MBA from Fairleigh Dickinson University.

Catherine Do has served as a member of
our board of directors since January 2025. Dr. Do was trained as a medical doctor specializing in Public Health and Epidemiology
in France, with a keen interest in molecular epidemiology. Due to the absence of a joint PhD-MD program in France, she paused her residency
to earn a master’s in Biostatistics and Clinical Research and a PhD in Molecular Pharmacology. After spending a year at the French
Drug Agency (ANSM) as a pharmaco-epidemiologist, Dr. Do pursued her interest in molecular research, undertaking a post-doctoral fellowship
in genetics and epigenetics at Columbia University. From 2017 to 2022, she served as an assistant scientist at the Center for Discovery
and Innovation at Hackensack University Medical Center. In 2022, to further her expertise in chromatin architecture, she joined NYU Langone
Health as an Assistant Professor in Pathology focusing on chromatin architecture, underscoring her central role in the field of drug discovery.
Dr. Do earned a master’s in Biostatistics and Clinical Research and a PhD in Molecular Pharmacology at Paul Sabatier University
in Toulouse, France.

17

G. Sridhar Prasad has served as a member
of our board of directors since January 2025. Dr. Prasad joined Syrrx, Inc., a drug discovery company, in 2001, leading crystallography
efforts that led to the discovery of Nesina®, a drug to treat type 2 diabetes. At Merck & Co. Inc